-The Business Standard Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India. IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to...

-The Economic Times MUMBAI: A drug maker found overcharging will have to shell out the entire sales revenue of the medicine from the date of its launch as penalty, according to a directive issued by the country's drug price regulator. "If a company has not been booked for overcharging for selling the product without price approval, if any, pertaining to the period prior to fixation of the price of the said formulation,...

-The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control —...

-The Economic Times MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco. The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at...

-Live Mint Cipla Ltd won a landmark patent case against Swiss drug maker F Hoffmann-La Roche Ltd in the Delhi high court on Friday over the Indian company’s generic copy of lung cancer drug Tarceva after a four-year court battle. Justice Manmohan Singh observed in his 280-page judgement that it had been scientifically proven that Cipla’s generic version was a polymorph B variant of Roche’s patented drug and that it didn’t actually...